In this Point/Counterpoint, Drs. Madueke and Abern argue that active surveillance should not currently be considered for patients with intermediate-risk prostate cancer.
Ikenna Madueke, MD, PhD
Advertisement
Articles by Ikenna Madueke, MD, PhD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on CancerNetwork
1
MYTHIC Trial Demonstrates Efficacy in Platinum-Resistant Ovarian Cancer
2
What is the Future of TIL Therapy in Metastatic Melanoma?
3
Zoldonrasib Shows Promising Activity in KRAS G12D+ NSCLC
4
Precision Medicine with Duvelisib and the Evolving Landscape of Lymphoma
5